Stents are implantable devices designed to serve as endoluminal scaffolds in the recanalization of occluded or structurally compromised vascular and nonvascular circulatory conduits in various organs and tissues of the human body.  Nonvascular applications for stenting include biliary stenting, gastrointestinal stenting, pulmonary stenting, and urologic stenting.  In 2005, U.S. sales of nonvascular stents totaled approximately $152 million.  Over the forecast period covered by this report, this figure is expected to increase at a compound annual rate of 2.8%, reaching approximately $174 million in the year 2010. 

This 150-page report from Medtech Insight includes analyses of products, technologies, current and forecast markets, competitors, and opportunities in the U.S. nonvascular stents market.  Topics discussed in this report include current and emerging stenting technologies (e.g., stent design, materials, and coatings), biliary tract obstruction, gastrointestinal tract obstruction, pulmonary tract obstruction, and urinary tract obstruction. 

TABLE OF CONTENTS AND LIST OF EXHIBITS

EXECUTIVE SUMMARY

i.    Nonvascular Stents

a.   Biliary Stents

b.   Gastrointestinal Stents

c.    Pulmonary Stents

d.   Urologic Stents

ii.    Combined Market Analysis

Exhibit ES-1:    Biliary Stents, Market Forecast, 2004-2010

Exhibit ES-2:    Gastrointestinal Stents, Market Forecast, 2004-2010

Exhibit ES-3:    Pulmonary Stents, Market Forecast, 2004-2010

Exhibit ES-4:    Urologic Stents, Market Forecast, 2004-2010

Exhibit ES-5:    Nonvascular Stenting, Procedure Volumes Forecast, 2004-2010

Exhibit ES-6:    Nonvascular Stents, Market Forecast, 2004-2010

1. CURRENT AND EMERGING STENTING TECHNOLOGIES

1.1 Stent Design

1.1.1 Vascular Stents

1.1.2 Nonvascular Stents

1.1.3 Stent Deployment Mechanisms

1.2 Stent Materials

1.2.1 Metal Stents

1.2.1.1 Absorbable Magnesium Alloys

1.2.1.2 Cobalt Alloys

1.2.1.3 Nickel-Titanium Alloys

1.2.1.4 Stainless Steel

1.2.2 Standard Polymeric Stents

1.2.3 Biodegradable Polymeric Stents

1.3 Stent Coatings

1.3.1 Radiopacity Enhancement

1.3.2 Biocompatibility Enhancement

1.3.3 Active Therapeutic Enhancement

1.3.3.1 Drug-Eluting Stents

1.3.3.1.1 Anti-Restenotic Drug-Eluting Stents

1.3.3.1.2 Drug Delivery Techniques

1.3.4 Stent Coverings and Linings

Exhibit 1-1:   Selected Biomedical, Clinical, and Technical Stent Requirements

Exhibit 1-2:   Advantages and Disadvantages of Selected Vascular Stent Designs

Exhibit 1-3:   Advantages and Disadvantages of Metal Stent Materials

Exhibit 1-4:   Selected Polymeric Stent Materials

Exhibit 1-5:   Selected Characteristics of Antirestenosis Agents Used in Drug-Eluting Stents

Exhibit 1-6:   Advantages and Disadvantages of Nonresorbable and Biodegradable Polymeric Drug Carriers for Drug-Eluting Stents

2. NONVASCULAR STENTS MARKET

2.1 Nonvascular Conditions Targeted by Stenting

2.1.1 Biliary Tract Obstruction

2.1.1.1 Clinical Indications

2.1.1.2 Implantation Technique

2.1.1.3 Biliary Stent Types

2.1.1.3.1 Plastic Devices

2.1.1.3.2 Metal Devices

2.1.1.4 Procedure Volumes

2.1.2 Gastrointestinal Tract Obstruction

2.1.2.1 Colorectal Stenting

2.1.2.1.1 Clinical Indications

2.1.2.1.2 Technology

2.1.2.1.3 Implantation Technique

2.1.2.2 Esophageal Stenting

2.1.2.2.1 Technology

2.1.2.2.2 Implantation Technique

2.1.2.3 Procedure Volumes

2.1.3 Pulmonary Tract Obstruction

2.1.3.1 Clinical Indications

2.1.3.2 Types of Pulmonary Stenting Systems

2.1.3.3 Procedure Volumes

2.1.4 Urinary Tract Obstruction

2.1.4.1 Ureteral Obstruction

2.1.4.1.1 Urinary Stone Disease

2.1.4.1.1.1 Treatment

2.1.4.1.2 Ureteral Strictures

2.1.4.1.2.1 Treatment

2.1.4.1.3 Ureteral Stenting

2.1.4.1.3.1 Implantation Technique

2.1.4.1.3.2 Indwelling Time

2.1.4.2 Urethral Obstruction

2.1.4.2.1 Benign Prostatic Hyperplasia

2.1.4.2.1.1 Treatment

2.1.4.2.2 Urethral Strictures

2.1.4.2.2.1 Treatment

2.1.4.2.3 Urethral Stenting

2.1.4.3 Procedure Volumes

2.2 Market Analysis

2.2.1 Biliary Stents

2.2.1.1 Products

2.2.1.2 Market Forecast

2.2.1.2.1 Competitive Analysis

2.2.2 Gastrointestinal Stents

2.2.2.1 Products

2.2.2.2 Market Forecast

2.2.2.2.1 Competitive Analysis

2.2.3 Pulmonary Stents

2.2.3.1 Products

2.2.3.2 Market Forecast

2.2.3.2.1 Competitive Analysis

2.2.4 Urologic Stents

2.2.4.1 Ureteral Stenting Products

2.2.4.2 Urethral Stenting Products

2.2.4.3 Market Forecast

2.2.4.3.1 Competitive Analysis

Exhibit 2-1:   2005, Biliary Obstruction, Facts and Figures

Exhibit 2-2:   Biliary Stenting, Procedure Volumes Forecast, 2004-2010

Exhibit 2-3:   2005, Colorectal Obstruction, Facts and Figures

Exhibit 2-4:   2005, Esophageal Obstruction, Facts and Figures

Exhibit 2-5:   Gastrointestinal Stenting, Procedure Volumes Forecast, 2004-2010

Exhibit 2-6:   2005, Pulmonary Tract Obstruction, Facts and Figures

Exhibit 2-7:   Pulmonary Stenting, Procedure Volumes Forecast, 2004-2010

Exhibit 2-8:   2005, Upper Urinary Tract Obstructions, Facts and Figures

Exhibit 2-9:   2005, Lower Urinary Tract Obstructions, Facts and Figures

Exhibit 2-10: Urologic Stenting, Procedure Volumes Forecast, 2004-2010

Exhibit 2-11: Nonvascular Stenting, Procedure Volumes Forecast, 2004-2010

Exhibit 2-12: Nonvascular Stents, Market Forecast, 2004-2010

Exhibit 2-13: 2006, Selected Metal Biliary Stents

Exhibit 2-14: Biliary Stents, Market Forecast, 2004-2010

Exhibit 2-15: 2005, Biliary Stents Market, Share by Supplier

Exhibit 2-16: 2006, Selected Colorectal Stents

Exhibit 2-17: 2006, Selected Metal Esophageal Stents

Exhibit 2-18: Gastrointestinal Stents, Market Forecast, 2004-2010

Exhibit 2-19: 2005, Colorectal Stents Market, Share by Supplier

Exhibit 2-20: 2005, Esophageal Stents Market, Share by Supplier

Exhibit 2-21: 2006, Selected Pulmonary Stents

Exhibit 2-22: Pulmonary Stents, Market Forecast, 2004-2010

Exhibit 2-23: 2005, Pulmonary Stents Market, Share by Supplier

Exhibit 2-24: 2006, Selected Ureteral Stents

Exhibit 2-25: Urologic Stents, Market Forecast, 2004-2010

Exhibit 2-26: 2005, Ureteral Stents Market, Share by Supplier

3. COMPANY PROFILES

3.1    Abbott Laboratories

3.2    ACMI Corporation/Gyrus Group

3.3    American Medical Systems, Inc.

3.4    C.R. Bard, Inc.

3.5    Boston Scientific Corporation

3.6    Bryan Corporation

3.7    Cook Group

3.8    Cordis Corporation/Johnson & Johnson

3.9    eV3, Inc.

3.10  W.L. Gore & Associates, Inc.

3.11  Guidant Corporation/Boston Scientific Corporation

3.12  Hood Laboratories, Inc.

3.13  Medtronic, Inc.

APPENDIX:  COMPANY LISTING

Copyright 2006, Medtech Insight, LLC